MK-677 (Ibutamoren): an oral growth-hormone secretagogue
It mimics ghrelin to stimulate GH release — and it comes in a pill, which makes it unusual in this space.
TL;DR
- MK-677 is not a peptide — it’s a small-molecule ghrelin-receptor agonist that prompts the pituitary to release growth hormone.
- Published trials in healthy older adults show it raises IGF-1 levels, but side effects include increased appetite, water retention, and blood-glucose changes.
- Oral activity is its key distinguishing feature; most GH secretagogues require injection.
What it is
MK-677, also called Ibutamoren, is a non-peptide compound developed in the 1990s. The distinction matters: unlike sermorelin or CJC-1295, which are peptide chains that mimic growth-hormone-releasing hormone (GHRH), MK-677 is a small molecule that activates the ghrelin receptor (GHS-R1a). Ghrelin is sometimes called the “hunger hormone,” and activating its receptor sends a signal up the hypothalamic-pituitary axis to release growth hormone. Because MK-677 survives digestion, it can be taken orally — a meaningful practical difference from injectable secretagogues.
How it works
The ghrelin receptor sits on pituitary somatotroph cells. When MK-677 binds it, the pituitary releases growth hormone in pulses. That GH then travels to the liver and stimulates production of insulin-like growth factor 1 (IGF-1). Importantly, MK-677 works upstream of GH itself — it prompts your own pituitary to secrete GH rather than delivering exogenous GH directly.
Who asks about it
People come to MK-677 when they want the potential benefits of GH secretagogue research without daily injections. It often comes up in conversations about recovery, body composition, and sleep quality — topics tied to age-related GH decline (sometimes called somatopause). The oral format also appeals to those who are uncomfortable with self-injection protocols.
What the research says
A frequently cited randomized controlled trial by Murphy et al. (2001) in The Journal of Clinical Endocrinology & Metabolism examined healthy older adults given 25 mg/day of MK-677 for two years. IGF-1 levels rose significantly compared to placebo. The authors also reported improvements in lean body mass and a reduction in fat mass, though the effect sizes were modest. Crucially, the same study documented meaningful side effects: increased appetite, transient lower-extremity edema, and a small but statistically significant increase in fasting blood glucose — a finding that warrants attention in anyone with pre-diabetes or insulin resistance. No large-scale Phase III trials in general healthy populations have been completed as of this writing.
What to know before considering it
MK-677 is not approved by the FDA for any general wellness indication. Access requires a licensed clinician evaluation, and baseline bloodwork — including fasting glucose, HbA1c, and IGF-1 — is standard before any protocol. The blood-glucose signal in published trials means it is not appropriate without metabolic monitoring. It is compounded under state-licensed 503A pharmacy protocols for certain indications; your clinician determines whether it is appropriate for you.
The Halftime POV
Most GH-axis conversations focus on injectables, but MK-677’s oral bioavailability makes it a genuinely different option worth understanding. The published IGF-1 data is real — so are the side effects. This is exactly the kind of compound where having a clinician read your labs before and during any protocol isn’t optional; it’s the whole point. Informed, supervised use is where the research value actually lives.
Related reading:
FAQ
Q: What is MK-677? A: MK-677 (ibutamoren) is an oral ghrelin-receptor agonist — it mimics ghrelin and stimulates the GHS-R1a receptor to trigger GH and IGF-1 release. Unlike most GH-related peptides, it is not a peptide by strict definition and can be taken orally because it is small enough to survive digestion.
Q: What does the research show about MK-677? A: Published studies have documented IGF-1 elevation in healthy adults and in older adults with low baseline IGF-1 following MK-677 administration. A Rudman-type study population (older adults with reduced GH secretion) showed sustained IGF-1 increases. Water retention and increased appetite are commonly reported in published literature.
Q: Does MK-677 require a prescription? A: Yes. Despite being orally bioavailable, MK-677 is a prescription compound requiring a clinician evaluation. It is not available as an over-the-counter supplement. Compounded MK-677 is not FDA-approved.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
Sources
- Murphy MG et al. “MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.” — J Clin Endocrinol Metab, 2001
- Nass R et al. “Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults.” — Ann Intern Med, 2008
